Skip to content

Research on the pathogenesis and drug efficacy mechanism of postpartum hemorrhage

Research on the pathogenesis and drug efficacy mechanism of postpartum hemorrhage

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109784
Enrollment
Unknown
Registered
2025-09-25
Start date
2025-10-14
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Atony-Induced Postpartum Hemorrhage

Interventions

Whole-pregnancy blood sample group:None
Intrapartum uterine tissue and blood sample group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for the "whole pregnancy blood sample" group:; (1) Age 18 to 55 years; (2) Nulliparous primigravidas carrying a singleton pregnancy; (3) Voluntarily joining and signing the informed consent form. 2. Inclusion criteria for the "labor uterine tissue and blood sample" group:; (1) Age 18 to 55 years; (2) Nulliparous primigravidas carrying a singleton pregnancy; (3) Gestational weeks between 37-<42; (4) Voluntarily joining and signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria for the "whole pregnancy blood samples" group:; (1) Suffering from serious diseases, such as tumors, severe heart dysfunction, severe liver and kidney impairment, etc.; 2. Exclusion criteria for the "delivery period uterine tissue and blood samples" group:; (1) Abnormalities in the placenta found during prenatal check-ups (placenta previa, placenta accreta, etc.); (2) Patients with significant coagulation dysfunction and prenatal thrombotic diseases during pregnancy; (3) Patients with pregnancy-related hypertension diseases during pregnancy (eclampsia, preeclampsia, pregnancy-induced hypertension, etc.); (4) Suffering from serious diseases, such as tumors, severe heart dysfunction, severe liver and kidney impairment, etc.

Design outcomes

Primary

MeasureTime frame
Postpartum hemorrhage;

Secondary

MeasureTime frame
Hemoglobin;Combination Use of Uterotonic Drugs;

Countries

China

Contacts

Public ContactTan Jing

West China Hospital of Sichuan University

tanjing84@outlook.com+86 28 85422129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026